Touch Medical Media Services's video: Mikkael Sekeres ASCO20: New combination therapy in patients with MDS CMML or LB AML

It was a pleasure to speak to Mikkael Sekeres to discuss the presentation of the phase II study of pevonedistat + azacitidine versus azacitidine in patients with higher-risk myelodysplastic syndromes/chronic myelomonocytic leukemia, or low-blast acute myelogenous leukemia (Clinicaltrials.gov identifier: NCT02610777). Questions 1. What are the limitations of hypomethylating agents such as, 5-azacitidine in the treatment of haematological malignancies? (0:06) 2. Could you tell us a little about pevonedistat and its mechanism of action? (0:56) 3. What were the aims and design of the Phase II study you are presenting at the ASCO20 Virtual Meeting? (1:30) 4. What were the major efficacy and safety findings of this study? (2:18) 5. What will be the next steps in the clinical development of pevonedistat? (4:04) Speaker disclosure: Mikkael Sekeres has served on the advisory boards for Celgene/BMS and Takeda.Millennium. Support: Interview and filming supported by Touch Medical Media. Commissioned in liaison with W2O Group. Filmed in coverage of the 2020 ASCO Virtual Scientific Program.